|
Renal Colic
|
G11.561.790.444.850 |
|
|
Pain
|
G11.561.790.444 |
|
|
Personnel Turnover
|
N04.452.677.680 |
|
|
MEF2 Transcription Factors
|
D12.776.930.397.700 |
|
|
Aminoacylation
|
D049148 |
[A reaction that introduces an aminoacyl group to a molecule. TRANSFER RNA AMINOACYLATION is the first step in GENETIC TRANSLATION.
, A reaction that produces an "activated" amino acid derivative, such as amino acyl adenylate, or amino acylphosphorylate and provides energy for the amino acid to be incorporated into a peptide, protein, or other macromolecule.
] |
|
Colestipol
|
J01.637.051.720.200 |
|
|
Agglutination
|
G12.122.100 |
|
|
Diet, Macrobiotic
|
E02.642.249.300.500 |
|
|
Beclin-1
|
D12.776.476.075.335 |
|
|
Isodesmosine
|
D12.125.072.415 |
|
|
Schizotypal Personality Disorder
|
F03.675.725 |
|
|
Bone Screws
|
E07.858.442.660.460.437 |
|
|
Influenza A Virus, H7N9 Subtype
|
D064766 |
[A subtype of INFLUENZA A VIRUS with the surface proteins hemagglutinin 7 and neuraminidase 9. This avian origin virus was first identified in humans in 2013.
] |
|
Gardner Syndrome
|
C04.588.274.476.411.307.089.393 |
|
|
Adenomatous Polyposis Coli
|
C04.588.274.476.411.307.089 |
|
|
Hydrobromic Acid
|
D01.029.260.300 |
|
|
Influenza A Virus, H9N2 Subtype
|
B04.820.480.968.405.400.900 |
|
|
Evidence-Based Facility Design
|
N02.278.200.252 |
|
|
Oncolytic Virotherapy
|
D050130 |
[Use of attenuated VIRUSES as ANTINEOPLASTIC AGENTS to selectively kill CANCER cells.
] |
|
Succinylcholine
|
D02.241.081.337.759.875 |
|
